Biotech entrepreneur Geoffrey von Maltzahn believes his company, Tessera Therapeutics, has a gene editing technology more powerful than CRISPR-Cas9, and after years of secretive lab development, is ready to unveil the first evidence of its “gene writing” potential.
It is now ten years since Jennifer Doudna and Emmanuelle Charpentier first published their work on CRISPR-Cas9, which works like molecular scissors to edit genes, and the first treatments aimed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?